Linezolid is a new antimicrobial agent with a broad
spectrum of activity against all clinically important gram positive
bacteria, including methicillin resistant Staphylococcus aureus
(MRSA) and vancomycin resistant enterococci (VRE). The incidence
of linezolid induced thrombocytopenia was reported to be
2.4% in phase III trials. Clearance of linezolid is not altered in
patents with renal insufficiency and no dose adjustment is necessary.
Therefore, linezolid is a suitable and reasonable drug of
choice for patients with renal insufficiency who have MRSA or
VRE infection. Moreover, renal insufficiency is also known to
cause thrombocytopenia.
